Antiviral therapy targeting viral polymerase

Current Pharmaceutical Design

Volumn 12, Issue 11, 2006, Pages 1339-1355

  Tsai, Ching Hsiu ^a   Lee, Pei Yu ^b   Stollar, Victor ^c,d   Li, Mei Ling ^c  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CHUNGTAI INST HLTH SCI TECHNOL   (Taiwan)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

HBV polymerase; Hepatitis C virus; HIV 1 drug resistance; HIV 1 Reverse Transcriptase; Nucleoside Inhibitors; Ribavirin

Indexed keywords

ABACAVIR; ACICLOVIR; ADEFOVIR; ANTIVIRUS AGENT; CIDOFOVIR; CP 94707; DIDANOSINE; DNA POLYMERASE; ELVUCITABINE; EMTRICITABINE; ETRAVIRINE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; INTERFERON; LAMIVUDINE; PENCICLOVIR; RIBAMIDINE; RIBAVIRIN; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; RNA POLYMERASE; STAVUDINE; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE; DNA DIRECTED DNA POLYMERASE; DNA DIRECTED RNA POLYMERASE; ENZYME INHIBITOR;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CROSS RESISTANCE; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE MUTATION; GENE TARGETING; HEMOLYTIC ANEMIA; HEPADNAVIRUS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA VIRUS; PRIORITY JOURNAL; RETROVIRUS; REVIEW; STRUCTURE ANALYSIS; VIRUS REPLICATION; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; ORTHOMYXOVIRUS; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; DNA-DIRECTED RNA POLYMERASES; DRUG DESIGN; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS B VIRUS; HERPESVIRIDAE; HIV-1 REVERSE TRANSCRIPTASE; ORTHOMYXOVIRIDAE; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33744975880     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776361156     Document Type: Review

References (240)

1. Cheetham GM, Steitz TA. Insights into transcription: structure and function of single-subunit DNA-dependent RNA polymerases. Curr Opin Struct Biol 2000; 10: 117-123.
2. Doublie S, Sawaya MR, Ellenberger T. An open and closed case for all polymerases. Structure Fold Des 1999; 7: R31-R35.
3. Ollis DL, Kline C, Steitz TA. Domain of E. coli DNA polymerase I showing sequence homology to T7 DNA polymerase. Nature 1985; 313:818-819.
4. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerese encoding elements. EMBO J 1989; 8: 3867-3874.
5. Steitz TA. A mechanism for all polymerases. Nature 1998; 391: 231-232.
6. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
7. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993; 67: 2832-2843.
8. Egger D, Bienz K. Recombination of poliovirus RNA proceeds in mixed replication complexes originating from distinct replication start sites. J Virol 2002, 76: 10960-10971.
9. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003; 77: 5487-5492.
10. Behrens SE, Tomei L, Do Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996; 15: 12-22.
11. Ivashkina N, Wolk B, Lohmann V, Bartenschlager R, Blum HE, Penin F, et al. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrame segment. J Virol 2002; 76: 13088-13093.
12. Schmidt-Mende J, Bieck E, Hugle T, Penin F, Rice CM, Blum HE, et al. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 2001; 276: 44052-44063.
13. Wattenberg B, Lithgow T. Targeting of C-terminal (tail)-anchored proteins: understanding how cytoplasmic activities are anchored to inbracellular membranes. Traffic 2001; 2: 66-71.
14. Moradpour D, Brass V, Bieck E, Friebe P, Gosert R, Blum HE, et al. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J Virol 2004; 78: 13278-13284.
15. Ferrari E, Wright-Minogue J, Fang JW, Baroudy BM, Lau JY, Hong Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol 1999; 73: 1649-1654.
16. Yamashita T, Kaneko S, Shirota Y, Qin W, Nomura T, Kobayashi K, et al. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J Biol Chem 1998; 273: 15479-15486.
17. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure ofthe RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937-943.
18. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure Fold Des 1999; 7: 1417-1426.
19. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 1999; 96: 13034-13039.
20. Tomei L, Vitale RL, Incitti I, Serafini S, Altamura S, Vitelli A,et al. Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J Gen Virol 2000; 81: 759-767.
21. Wang M, Ng KK, Cherney MM, Chan L, Yannopoulos CG, Bedard J, et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 2003; 278: 9489-9495.
22. Bressanelli S, Tomei L, Rey FA, De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribo-nucleotides. J Virol 2002; 76: 3482-3492.
23. Love RA, Parge HE, Yu X, Hickey MJ, Diehl W, Gao J, et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J Virol 2003; 77: 7575-7581.
24. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 2003; 58: 1-16.
25. Wu JZ, Hong Z. Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Curr Drug Targets Infect Disord 2003; 3: 207-219.
26. De Francesco R, Rice CM, New therapies on the horizon for hepatitis C. are we close? Clin.Liver Dis 2003; 7: 211-42, xi.
27. Hugle T, Cerny A. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev Med Virol 2003; 13: 361-371.
28. Ni ZJ, Wagman AS. Progress and development of small molecule HCV antivirals. Curr Opin Drug Discov Devel 2004; 7: 446-459.
29. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-1974.
30. Dhanak D, Duffy KJ, Johnston VK, Lin-Goerke J, Darcy M, Shaw AN, et al. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 2002; 277: 38322-38327.
31. Moradpour D, Gosert R, Egger D, Penin F, Blum HE, Bienz K. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Res 2003; 60: 103-109.
32. Cameron CE, Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 2001; 14: 757-764.
33. Mang D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276: 46094-46098.
34. Lin CC, Yeh LT, Vitarella D, Hong Z. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 2003; 14: 145-152.
35. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, et al. Inhibition of hepatitis C virus RNA replication by 2′'-modified nucleoside analogs. J Biol Chem 2003; 278: 11979-11984.
36. Eldrup AB, Prhavc M, Brooks J, Bhat B, Prakash TP, Song Q, et al. Structure-activity relationship of heterobase-modified 2′-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J Med Chem 2004; 47: 5284-5297.
37. Summa V, Petrocchi A, Matassa VG, Taliani M, Laufer R, De Francesco R, et al HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids. to 4,5-dihydroxy-pyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis. J Med Chem 2004; 47: 5336-5339.
38. Pace P, Nizi E, Pacini B, Pesci S, Matassa V, De Francesco R, et al. The monoethyl ester of meconic acid is an active site inhibitor of HCV NS5B RNA-dependent RNA polymerase. Bioorg Med Chem Lett 2004; 14: 3257-3261.
39. Beaulieu PL, Tsantrizos YS. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr Opin Investig Drugs 2004; 5: 838-850.
40. Gu B, Johnston VK, Gutshall LL, Nguyen TT, Gontarek RR, Darcy MG, et al. Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J Biol Chem 2003; 278: 16602-16607.
41. Crotty S, Mang D, Arnold JJ, Zhong W, Lan JY, Hong Z, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen Clinical, biological, and biochemical effect of pyrazofurin. Nat Med 2000; 6: 1375-1379.
42. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76: 8505-8517.
43. Airaksinen A, Pariente N, Menendez-Arias L, Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 2003; 311: 339-349.
44. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, et al. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 1973; 70: 1174-1178.
45. Stuyver LJ, McBrayer TR, Tharnish PM, Hassan AE, Chu CK, Pankiewicz KW, et al. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J Virol 2003; 77: 10689-10694.
46. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, %19;339: 1485-1492.
47. Pfeiffer JK, Kirkegaard K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol 2005; 79: 2346-2355.
48. Dubensky TW, Jr., Driver DA, Polo JM, Belli BA, Latham EM, Ibanez CE, et al. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol 1996; 70: 508-519.
49. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 2003; 100: 7289-7294.
50. Shimakami T, Hijikata M, Lou H, Ma YY, Kaneko S, Shimotohno K, et al. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol 2004; 78: 2738-2748.
51. Shirota Y, Luo H, Qin W, Kaneko S, Yamashita T, Kobayashi K, et al. Hepatitis C virus (HCV) NS5A binds RNA-depandent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 2002; 277: 11149-11155.
52. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001; 98: 9599-9604.
53. Park KJ, Choi SH, Lee SY, Hwang SB, Lai MM. Nonstructural 5A protein of hepatitis C virus modulates tumor necrosis factor alpha-stimulated nuclear factor kappa B activation. J Biol Chem 2002; 277: 13122-13128.
54. Tan SL, Nakao H, He Y, Vijayari S, Neddermann P, Jacobs BL, et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA 1999; 96: 5533-5538.
55. Ghosh AK, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 1999; 80: 1179-1183.
56. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001; 75: 1401-1407.
57. Gale MJ, Jr., Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the non-structural 5A protein. Virology 1997; 230: 217-227.
58. Taguchi T, Nag-Fujii M, Akutsu M, Kadoya H, Ohgimoto S, Ishido S, et al. Hepatitis C virus NS5A protein interacts with 2′,5′-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J Gen Virol 2004; 85: 959-969.
59. Chung YL, Shen ML, Yen SH. Hepatitis C virus NS5A as a potential viral Bc1-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer 2003; 107: 65-73.
60. Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC, et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002; 21: 4801-4811.
61. Beaulieu PL, Tsantrizos YS. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr Opin Investig Drugs 2004; 5: 838-850.
62. Kulpa D, Topping R, Telesnitsky A. Determination of the site of first strand transfer during Moloney murine leukemia virus reverse transcription and identification of strand transfer-associated reverse transcriptase errors. EMBO J 1997; 16: 856-865.
63. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-1790.
64. Jacobo-Molina A, Ding J, Nanni RG, Clark AD, Jr., Lu X, Tantillo C, et al. Crystal structure of human immmunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90: 6320-6324.
65. Sarafianos SG, Das K, Hughes SH, Arnold E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse franscriptases. Curr Opin Struct Biol 2004; 14: 716-730.
66. Goldschmidt V, Marquet R. Primer unblocking by HIV-1 raverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol 2004; 36: 1687-1705.
67. Do Clercq E. New anti-HIV agents and targets Med Res Rev 2002; 22: 531-565.
68. Parniak MA, Sluis-Cremer N. Inhibitors of HIV-1 reverse transcriptase. Adv.Pharmacol 2000; 49: 67-109.
69. Guillermont J, Pasquier E, Palandjian P, Vernier D, Gaurrand S, Lewi PJ, et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus Type 1. J Med Chem 2005; 48: 2072-2079.
70. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immmunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
71. Shulman N, Winters M. A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors. Curr Drug Targets Infect Disord 2003; 3: 273-281.
72. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
73. De Clercq E. Strategies in the design of antiviral drugs. Nat Rev Drug Discov 2002; 1: 13-25.
74. Neyts J, De Clercq E. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication. BioChem Pharmacol 1994; 47: 39-41.
75. Sarafianos SG, Das K, Clark AD, Jr., Ding J, Boyer PL, Hughes SH, Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 1999; 96: 10027-10032.
76. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 2000; 97: 3056-3061.
77. Shafer RW, Jung DR, Betts BJ, Xi Y, Gonzales MJ. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2000; 28: 346-348.
78. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994; 243: 369-387.
79. Sarafianos SG, Das K, Ding J, Boyer PL, Hughes SH, Arnold E. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem Biol 1999; 6: R137-R146.
80. Arion D, Kaushik N, McCormick S, Borkow G, Pamiak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): icreased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37: 15908-15917.
81. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998; 95: 13471-13476.
82. Meyer PR, Matsuura SE, Mian AM, So AG, Scoff WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4: 35-43.
83. Boyer PL, Gao HQ, Clark PK, Sarafianos SG, Arnold E, Hughes SH. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro. J Virol 2001; 75: 6321-6328.
84. Hsiou Y, Ding J, Das K, Clark AD, Jr., Hughes SH, Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996; 4: 853-860.
85. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, Woolf DJ, et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1995; 92: 1222-1226.
86. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-1790.
87. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PA, et al. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol 1995; 2: 407-415.
88. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995; 2: 293-302.
89. Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D, et al. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995; 3: 915-926.
90. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995; 2: 293-302.
91. Das K, Ding J, Hsiou Y, Clark AD, Jr., Moereels H, Koymans L, et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistent mutant. J Mol Biol 1996; 264: 1085-1100.
92. Esnouf RM, Ren J, Hopkins AL, Ross CK, Jones EY, Stammers DK, et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl) piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci USA 1997; 94: 3984-3989.
93. Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, Noreen R, et al. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 2002; 269: 1670-1677.
94. Ren J, Diprose J, Warren J, Esnouf RM, Bird LE, Ikemizu S, et al. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses. J Biol Chem 2000; 275: 5633-5639.
95. Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure Fold Des 2000; 8: 1089-1094.
96. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem 1996; 39: 1589-1600.
97. Hsiou Y, Das K, Ding J, Clark AD, Jr., Kleim JP, Rosner M, et al. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol 1998; 284: 313-323.
98. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem 1996; 39: 1589-1600.
99. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 2001; 312: 795-805.
100. Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistent HIV-1 variants. J Med Chem 2004; 47: 2550-2560.
101. Ding J, Das K, Tantillo C, Zhang W, Clark AD, Jr., Jessen S, et al. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution. Structure 1995; 3: 365-379.
102. Das K, Clark AD, Jr., Lewi PJ, Heeres J, De Jonge MR, Koymans LM, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-2560.
103. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA 1995; 92: 8046-8049.
104. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267: 988-993.
105. Ding J, Das K, Hsiou Y, Sarafianos SG, Clark AD, Jr., Jacobo-Molina A, et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. J Mol Biol 1998; 284: 1095-1111.
106. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267: 988-993.
107. Das K, Ding J, Hsiou Y, Clark AD, Jr., Moereels H, Koymans L, et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol 1996; 264: 1085-1100.
108. Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D, et al. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995; 3: 915-926.
109. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA 2002; 99: 14410-14415.
110. Auwerx J, Stevens M, Van Rompay AR, Bird LE, Ren J, De Clercq E, et al. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT. J Virol 2004; 78: 7427-7437.
111. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure.(Camb.) 2002; 10: 369-381.
112. Tuske S, Sarafianos SG, Clark AD, Jr., Ding J, Naeger LK, White KL, et al. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol 2004; 11: 469-474.
113. Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 2001; 11: 2235-2239.
114. Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, Dmitrienko GI, et al. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tertbutylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry 1997; 36: 3179-3185.
115. Pata JD, Stirtan WG, Goldstein SW, Steitz TA. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 2004; 101: 10548-10553.
116. Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 1983; 305: 827-829.
117. Xiong Y, Eickbush TH. Origin and evolution of retroelements based upon their reverse transcriptase sequences. EMBO J 1990; 9: 3353-3362.
118. Bartenschlager R, Schaller H. The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription. EMBO J 1988; 7: 4185-4192.
119. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994; 68: 2026-2030.
120. Chang LJ, Pryciak P, Ganem D, Varmus HE. Biosynthesis of the reverse transcriptase of hepatitis B viruses involves de novo translational initiation not ribosomal frameshifting. Nature 1989; 337: 364-368.
121. Chang LJ, Hirsch RC, Ganem D, Varmus HE. Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J Virol 1990; 64; 5553-5558.
122. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 1990; 64: 613-620.
123. Roychoudhury S, Faruqi AF, Shih C. Pregenomic RNA encapsidation analysis of eleven missense and nonsense polymerase mutants of human hepatitis B virus. J Virol 1991; 65: 3617-3624.
124. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986; 232: 477-484.
125. Tavis JE, Perri S, Ganem D. Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer. J Virol 1994; 68: 3536-3543.
126. Lanford RE, Kim YH, Lee H, Notvall L, Beames B. Mapping of the hepatitis B virus reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and by protein-protein interaction. J Virol 1999; 73: 1885-1893.
127. Bartenschlager R, Junker-Niepmann M, Schaller H. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J Virol 1990; 64: 5324-5332.
128. De Clercq E. Antiviral drugs: current state of the art. J.Clin.Virol 2001; 22: 73-89.
129. Severini A, Liu XY, Wilson JS, Tyrrell DL. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob.Agents Chemother 1995; 39: 1430-1435.
130. Zoulim F, Dannaoui E, Borel C, Hantz O, Lin TS, Liu SH, et al. 2′,3′-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob.Agents Chemother 1996; 40: 448-453.
131. Seigneres B, Aguesse-Germon S, Pichoud C, Vuillermoz I, Jamard C, Trepo C, et al. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J Hepatol 2001; 34: 114-122.
132. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-1673.
133. Birkus G, Gibbs CS, Cihlar T. Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitachondrial DNA in liver and skeletal muscle cells. J.Viral Hepat 2003; 10: 50-54.
134. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998; 42: 3200-3208.
135. Condreay LD, Condreay JP, Jansen RW, Paff MT, Averett DR: (-)-cis -5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrob.Agents Chemother 1996; 40: 520-523.
136. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36: 710-722.
137. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36: 710-722.
138. Le Guerhier F, Pichoud C, Jamard C, Guerret S, Chevallier M, Peyrol S, et al. Antiviral activity of beta-L-2′,3′-dideoxy- 2′,3′-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob.Agents Chemother 2001; 45: 1065-1077.
139. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001; 12 Suppl 1: 119-29.: 119-129.
140. Schroder I, Holmgren B, Oberg M, Lofgren B. Inhibition of human and duck hepatitis B virus by 2′,3′-dideoxy-3′-fluoroguanosine in vitro. Antiviral Res 1998; 37: 57-66.
141. Hantz O, Borel C, Trabaud C, Zoulim F, Dessolin J, Camplo M, et al. Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles. Antimicrob.Agents Chemother 1997; 41: 2579-2581.
142. Zhou T, Saputelli J, Aldrich CE, Deslauriers M, Condreay LD, Mason WS. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob.Agents Chemother 1999; 43: 1947-1954.
143. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin.Infect Dis 2003; 36: 687-696.
144. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-1673.
145. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677.
146. Fu L, Liu SH, Cheng YC. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. BioChem Pharmacol 1999; 57: 1351-1359.
147. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-11841.
148. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. BioChem Pharmacol 1998; 55: 1567-1572.
149. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75: 4771-4779.
150. Lee K, Chu CK. Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. Antimicrob.Agents Chemother 2001; 45: 138-144.
151. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9: 149-160.
152. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 1-15.
153. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob.Agents Chemother 2002; 46: 1734-1740.
154. Yamamoto T, Litwin S, Zhou T, Zhu Y, Condreay L, Furman P, et al. Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J Virol 2002; 76: 1213-1223.
155. Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus. Intervirology 1997; 40: 337-342.
156. Pichoud C, Seigneres B, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999; 29: 230-237.
157. Mutimer D. Hepatitis B virus infection: resistance to antiviral agents. J.Clin. Virol 2001; 21: 239-242.
158. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 1-15.
159. zu PJ, Wands JR. Specific inhibition of hepatitis B virus replication by sense RNA. Antisense Nucleic Acid Drug Dev 1999; 9: 241-252.
160. Braithwaite DK, Ito J. Compilation, alignment, and phylogenetic relationships of DNA polymerases. Nucleic Acids Res 1993; 21: 787-802.
161. Haffey ML, Novotny J, Bruccoleri RE, Carroll RD, Stevens JT, Matthews JT. Structure-function studies of the herpes simplex virus type 1 DNA polymerase. J Virol 1990; 64: 5008-5018.
162. Wang ZQ, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, Wagner EF. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 1997; 11: 2347-2358.
163. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J.Infect Dis 2003; 188: 32-39.
164. Wang HL, O'Rear J, Stollar V. Mutagenesis of the Sindbis virus nsP1 protein: effects on methyltransferase activity and viral infectivity. Virology 1996; 217: 527-531.
165. Knopf CW, Weisshart K. The herpes simplex virus DNA polymerase: analysis of the functional domains. Biochim.Biophys.Acta 1988, %620;951: 298-314.
166. Hwang YT, Smith JF, Gao L, Hwang CB. Mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene can confer altered drug sensitivities. Virology 1998; 246: 298-305.
167. Franklin MC, Wang J, Steitz TA. Structure of the replicating complex of a pol alpha family DNA polymerase. Cell 2001; 105: 657-667.
168. Andrei G, Snoeck R, De Clercq E, Esnouf R, Fiten P, Opdenakker G. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J Gen Virol 2000; 81: 639-648.
169. Digard P, Bebrin WR, Weisshart K, Coen DM. The extreme C terminus of herpes simplex virus DNA polymerase is crucial for functional interaction with processivity factor UL42 and for viral replication. J Virol 1993; 67: 398-406.
170. Bridges KG, Chow CS, Coen DM. Identification of crucial hydrogen-bonding residues for the interaction of herpes simplex virus DNA polymerase subunits via peptide display, mutational, and calorimetric approaches. J Virol 2001; 75: 4990-4998.
171. De Clercq E. Antiviral drugs in current clinical use. J.Clin.Virol 2004; 30: 115-133.
172. Baker DA. Valacyclovir in the treatment of genital herpes and herpes zoster. Expert.Opin Pharmacother 2002; 3: 51-58.
173. Wu JZ, Hong Z. Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Curr Drug Targets Infect Disord 2003; 3: 207-219.
174. De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004; 2: 704-720.
175. Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem 1989; 264: 7405-7411.
176. Balzarini J, Haller-Meier F, De Clercq E, Meier C. Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir. Antivir Chem Chemother 2001; 12: 301-306.
177. Anand B, Nashed Y, Mitra A. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Curr Eye Res 2003; 26: 151-163.
178. Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert.Rev Anti.Infect Ther 2004; 2: 389-403.
179. Hostetler KY, Rybak RJ, Beadle JR, Gardner MF, Aldern KA, Wright KN, et al. In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections. Antivir Chem Chermother 2001; 12: 61-70.
180. Andrei G, De Clercq E, Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res 2004; 61: 181-187.
181. Harris SA, McGuigan C, Andrei G, Snoeck R, De Clercq E, Balzarini J. Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2′-deoxyuridine. Antivir Chem Chemother 2001; 12: 293-300.
182. Sim IS, Raper RH: 5-substituted deoxyuridines - structural requirements for antiviral activity against herpes simplex virus types 1 and 2 and possible biochemical basis for relative potency. Antiviral Res 1984; 4: 159-168.
183. Kumar R: 5-(1-substituted) alkyl pyrimidine nucleosides as antiviral (herpes) agents. Curr Med Chem 2004; 11: 2749-2766.
184. De Clercq E: (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU). Med Res Rev 2005; 25: 1-20.
185. Onishi T, Mukai C, Nakagawa R, Sekiyama T, Aoki M, Suzuki K, et al. Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. J Med Chem 2000; 43: 278-282.
186. Kumar R, Sharma N, Nath M, Saffran HA, Tyrrel DL. Synthesis and antiviral activity of novel acyclic nucleoside analogues of 5-(1-azido-2-haloethyl)uracils. J Med Chem 2001; 44: 4225-4229.
187. Balzarini J, McGuigan C. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochim Biophys Acta 2002; 1587: 287-295.
188. De Clercq E. Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues. Med Res Rev 2003; 23: 253-274.
189. Foster SA, Cerny J, Cheng YC. Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine. J Biol Chem 1991; 266: 238-244.
190. Neyts J, De Clercq E. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication. BioChem Pharmacol 1994; 47: 39-41.
191. Gunaga P, Moon HR, Choi WJ, Shin DH, Park JG, Jeong LS. Recent advances in 4′-thionucleosides as potential antiviral and antitumor agents. Curr Med Chem 2004; 11: 2585-2637.
192. Maslen HL, Hughes D, Hursthouse M, De Clercq E, Balzarini J, Simons C. 6-azapyrimidine-2′-deoxy-4′-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains. J Med Chem 2004; 47: 5482-5491.
193. Snoeck R, Andrei G, Clercq ED. Novel agents for the therapy of varicella-zoster virus infections. Expert.Opin Investig Drugs 2000; 9: 1743-1751.
194. Eriksson B, Larsson A, Helgstrand E, Johansson NG, Oberg B. Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase. Biochim.Biophys.Acta 1980; 607: 53-64.
195. Gao WY, Jaroszewski JW, Cohen JS, Cheng YC. Mechanisms of inhibition of herpes simplex virus type 2 growth by 28-mer phosphorothioate oligodeoxycytidine. J Biol Chem 1990; 265: 20172-20178.
196. Tucker JA, Clayton TL, Chidester CG, Schulz MW, Harrington LE, Conrad SJ, et al. Structure-activity relationships of acyloxyamidine cytomegalovirus DNA polymerase inhibitors. Bioorg Med Chem 2000; 8: 601-615.
197. Vaillancourt VA, Cudahy MM, Staley SA, Brideau RJ, Conrad SJ, Knechtel ML, et al. Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase. Bioorg Med Chem Lett 2000; 10: 2079-2081.
198. Oien NL, Brideau RJ, Hopkins TA, Wieber JL, Knechtel ML, Shelly JA, et al. Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob.Agents Chemother 2002; 46: 724-730.
199. Brideau RJ, Knechtel ML, Huang A, Vaillancourt VA, Vera EE, Oien NL, et al. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res 2002; 54: 19-28.
200. Knechtel ML, Huang A, Vaillancourt VA, Brideau RJ. Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU-183792, a 4-oxo-dihydroquinoline. J Med Virol 2002; 68: 234-236.
201. Digard P, Williams KP, Hensley P, Brooks IS, Dahl CE, Coen DM. Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interface. Proc Natl Acad Sci USA 1995; 92: 1456-1460.
202. Bridges KG, Hua Q, Brigham-Burke MR, Martin JD, Hensley P, Dahl CE, et al. Secondary structure and structure-activity relationships of peptides corresponding to the subunit inferface of herpes simplex virus DNA polymerase. J Biol Chem 2000; 275: 472-478.
203. Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS. Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit. J Virol 2003; 77: 8336-8344.
204. Pilger BD, Cui C, Coen DM. Identification of a small molecule that inhibits herpes simplex virus DNA Polymerase subunit interactions and viral replication. Chem Biol 2004; 11: 647-654.
205. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist.Updat 2002; 5: 88-114.
206. Chibo D, Druce J, Sasadeusz J, Birch C. Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res 2004; 61: 83-91.
207. Huang L, Ishii KK, Zuccola H, Gehring AM, Hwang CB, Hogle J, et al. The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of alpha-like DNA polymerases. Proc Natl Acad Sci USA 1999, %19;96: 447-452.
208. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26: 29-37.
209. Bestman-Smith J, Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 2003; 77: 7820-7829.
210. Hwang YT, Zuccola HJ, Lu Q, Hwang CB. A point mutation within conserved region VI of herpes simplex virus type 1 DNA polymerase confers altered drug sensitivity and enhances replication fidelity. J Virol 2004; 78: 650-657.
211. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999; 12: 286-297.
212. Baker RO, Hall JD. Impaired mismatch extension by a herpes simplex DNA polymerase mutant with an editing nuclease defect. J Biol Chem 1998; 273: 24075-24082.
213. De Bolle L, Manichanh C, Agut H, De Clercq E, Naesens L. Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral Res 2004; 64: 17-25.
214. Chibo D, Mijch A, Doherty R, Birch C. Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immuno-compromised patient. J Clin Virol 2002; 25: 165-170.
215. Saijo M, Suzutani T, Morikawa S, Kurane I. Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain. Antimicrob Agents Chemother 2005; 49: 606-611.
216. Mousavi-Jazi M, Schloss L, Wahren B, Brytting M. Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase. J.Clin.Virol 2003; 26: 301-306.
217. Chou S, Miner RC, Drew WL. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J.Infect Dis 2000; 182: 1765-1768.
218. Thomsen DR, Oien NL, Hopkins TA, Knechtel ML, Brideau RJ, Wathen MW, et al. Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. J Virol 2003; 77: 1868-1876.
219. De Clercq E. Antiviral drugs: current state of the art. J Clin Virol 2001; 22: 73-89.
220. Verri A, Focher F, Duncombe RJ, Basnak I, Walker RT, Coe PL, et al. Anti-(herpes simplex virus) activity of 4′-thio-2′-deoxyuridines: a biochemical investigation for viral and cellular target enzymes. BioChem J 2000; 351(Pt 2): 319-326.
221. Neyts J, De Clercq E. The anti-herpesvirus activity of (1′S,2′R)-9-1′,2′-bis(hydroxymethyl) -cycloprop)-1′-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil. Antiviral Res 2001; 49: 121-127.
222. Wang J, Froeyen M, Hendrix C, Andrei G, Snoeck R, De Clercq E, et al. The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine. J Med Chem 2000; 43: 736-745.
223. Shigeta S, Mori S, Watanabe F, Takahashi K, Nagata T, Koike N, et al. Synthesis and antiherpesvirus activities of 5-alkyl-2-thiopyrimidine nucleoside analogues. Antivir Chem Chemother 2002; 13: 67-82.
224. Russ P, Schelling P, Scapozza L, Folkers G, Clercq ED, Marquez VE. Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. J Med Chem 2003; 46: 5045-5054.
225. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-11841.
226. Espert L. Degols G. Gongora C, Blondel D, Williams BR, Silverman RH, et al. ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J Biol Chem 2003; 278: 16151-16158.
227. Zhou S, Breitenbach JM, Borysko KZ, Drach JC, Kern ER, Gullen E, et al. Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides. J Med Chem 2004; 47: 566-575.
228. Williams JD, Drach JC, Townsend LB. Synthesis and antiviral evaluation of some novel tricyclic pyrazolo[3,4-b]indole nucleosides. Nucleosides Nucleotides Nucleic Acids 2004; 23: 805-812.
229. Zemlicka J. Enantioselectivity of the antiviral effects of nucleoside analogues. Pharmacol. Ther 2000; 85: 251-266.
230. Schelling P, Claus MT, Johner R, Marquez VE, Schulz GE, Scapozza L. Biochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells. J Biol Chem 2004; 279: 32832-32838.
231. Appleton BA, Loregian A, Filman DJ, Coen DM, Hogle JM. The cytomegalovirus DNA polymerase subunit UL44 forms a C clamp-shaped dimer. Mol Cell 2004; 15: 233-244.
232. Loregian A, Appleton BA, Hogle JM, Coen DM. Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit. J Virol 2004; 78: 9084-9092.
233. Tomassini JE, Davies ME, Hastings JC, Lingham R, Mojena M, Raghoobar SL, et al. A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob.Agents Chemother 1996; 40: 1189-1193.
234. Li ML, Rao P, Krug RM. The active sites of the influenza cap-dependent endonuclease are on different polymerase subunits. EMBO J 2001; 20: 2078-2086.
235. Hagen M, Chung TD, Butcher JA, Krystal M. Recombinant influenza virus polymerase: requirement of both 5′ and 3′ vital ends for endonuclease activity. J Virol 1994; 68: 1509-1515.
236. Cianci C, Tiley L, Krystal M. Differential activation of the influenza virus polymerase via template RNA binding. J Virol 1995; 69: 3995-3999.
237. Li ML, Ramirez BC, Krug RM. RNA-dependent activation of primer RNA production by influenza virus polymerase: different regions of the same protein subunit constitute the two required RNA-binding sites. EMBO J 1998; 17: 5844-5852.
238. Brunetto MR, Bonino F. Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences. Curr Pharm Des 2004; 10(17): 2063-75.
239. Fabris P, Barnes E, Tositti G, Giordani MT, Grasso A, De Lalla F. Therapy of chronic hepatitis C virus infection in HIV co-infected people. Curr Pharm Des 2004; 10(17): 2111-22.
240. Gomez J, Nadal A, Sabariegos R, Beguiristain N, Martell M, Piron M. Three properties of the hepatitis C virus RNA genome related to antiviral strategies based on RNA-therapeutics: variability, structural conformation and tRNA mimicry. Curr Pharm Des 2004; 10(30): 3741-56.